Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent syndrome, representing nearly half of all HF cases. Characterized by symptoms of HF despite a normal ...

Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) reduction, and a comparison of renal denervation methods for resistant BP.

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an outcome. In MR studies, instrumental variables associated with the ...

The Jigawa State Government has announced plans to introduce free drugs for patients with diabetes, hypertension, and sickle cell disease across the state. The State Commissioner for Health ...

Electroretinograms were recorded in 24 subjects with essential hypertension (blood pressure >140/90 mm Hg) and in 9 age-matched normotensive control subjects (blood pressure <140/90 mm Hg). Diabetes ...